Addition of objective data to identify risk for medication misuse and abuse: The inconsistency score

Pain Medicine (United States)

Volumn 14, Issue 12, 2013, Pages 1900-1907

  Hamill Ruth, Robin J ^a   Larriviere, Kylyana ^a   Mcmasters, Mary G ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Comprehensive Behavioral Health ^*  (United States)

Author keywords

Benzodiazepines; Chronic Pain; Drug Abuse; Drug Misuse; Opioids; Prescription Monitoring Program; Risk Mitigation; Urine Drug Testing

Indexed keywords

ILLICIT DRUG; NON PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; DRUG MISUSE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT IDENTIFICATION; POINT OF CARE TESTING; PRESCRIPTION; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; URINALYSIS;

BENZODIAZEPINES; CHRONIC PAIN; DRUG ABUSE; DRUG MISUSE; OPIOIDS; PRESCRIPTION MONITORING PROGRAM; RISK MITIGATION; URINE DRUG TESTING;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC PAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84890247924     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12221     Document Type: Article

References (26)

1. Volkow ND. Prescription drug abuse-December 2011: A research update from the national institute on drug abuse. Topics in Brief, December 2011. Available at: http://www.drugabuse.gov/sites/default/files/prescription1.pdf (accessed March 12, 2013).
2. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future Study: Trends in prevalence of various drugs. National Institute on Drug Abuse. 2012. Available at: http://www.drugabuse.gov/related-topics/trends-statistics/monitoring-future (accessed March 12, 2013).
3. Paulozzi LJ, Machs KA, Jones CM. Vital signs: Risk for overdose from methadone used for pain relief-United States 1999-2010. MMWR Morb Mortal Wkly Rep 2012;61:493-497.
4. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2010: Area profiles of drug-related mortality. HHA Publication No. (SMA) 12-4699, DAWN Series D-36. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
5. Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict 2009;18:5-14.
6. Wunsch MJ, Nakamoto K, Nuzzo PA, etal. Prescription drug fatalities among women in rural Virginia: A study of medical examiner cases. J Opioid Manag 2009;5:228-236.
7. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309:657-659.
8. Webster L, Cochella S, Dasgupta N, etal. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med 2011;12:S26-35.
9. Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med 2008;9:1098-1106.
10. Lapham SC. Are drunk-driving offenders referred for screening accurately reporting their drug use? Drug Alcohol Depend 2002;66:243-253.
11. Akinci IH. Concordance between verbal report and urine screen of recent marijuana use in adolescents. Addict Behav 2001;20:53-69.
12. Staines GL. Polysubstance use among alcoholics. J Addict Dis 2001;20:53-69.
13. Ready LB, Sarkis E, Turner JA. Self-reported vs. actual use of medications in chronic pain patient. Pain 1982;12:285-294.
14. Fishbain DA, Cutler RB, Rosomoff HL, etal. Validity of self-reported drug use in chronic pain patients. Clin J Pain 1999;15:184-191.
15. Prestion KL, Silverman K, Shuster CR, etal. Comparison of self-reported drug use with quantitative and qualitative urinalysis for assessment of drug use in treatment studies. NIDA Res Monogr 1997;167:130-145.
16. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6:107-112.
17. Gourlay DL, Heit HA. Universal precautions revisited: Managing the inherited pain patient. Pain Med 2009;10(suppl 2):S115-123.
18. Model policy for the use of controlled substances for the treatment of pain. Federation of State Medical Boards of the United States, Inc. 2004. Available at: http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf (accessed March 12, 2013).
19. Green TC, Mann MR, Bowman SE, etal. How does use of a prescription monitoring program change medical practice? Pain Med 2012;13:1314-1323.
20. Meltzer EC, Rybin D, Meshesha LZ, etal. Aberrant drug-related behaviors: Unsystematic documentation does not identify prescription drug use disorder. Pain Med 2012;13:1436-1443.
21. Rice BJ, White AG, Birnbaum HG, etal. A model to identify patients at risk for prescription opioid abuse, dependence, and misuse. Pain Med 2012;13:1162-1173.
22. Leach D, Hamill-Ruth R, Haverstick D. Point of care urine drug screening is consistent with standard lab testing in patients who report drug intake accurately. Pain Med 2011;12:476.
23. Integrated EZ Split Key Cup package insert, BTNX Inc, Markham, ON, effective date 2006-02-16.
24. Pesce A, West C, Egan-City K, Clarke W. Diagnostic accuracy and interpretation of urine drug testing for pain patients: An evidence-based approach. 2012. Available at: http://cdn.intechweb.org/pdfs/28113.pdf (accessed March 14, 2013).
25. Butler SF, Budman SH, Fernandez K, etal. Validation of a screener and opioid assessment measure for patients with chronic pain. J Pain 2006;7:671-681.
26. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med 2005;6:432-442.